Novartis scuttles trial for program lauded by Vas Narasimhan as emerging transplant drug star
A program touted by Novartis CEO Vas Narasimhan as a near-slam dunk has flopped a Phase IIb study, leading the Swiss biopharma to discontinue the trial altogether.
The candidate in question, iscalimab or CFZ533, proved less effective than standard of care in preventing organ rejection after kidney transplants, Novartis announced Friday morning. Narasimhan had highlighted iscalimab in Novartis’ yearly R&D presentation last November as a potential mid-stage star, after tapping it a year earlier in December 2019 as an emerging star.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 128,800+ biopharma pros reading Endpoints daily — and it's free.